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Abstract
Objective/Background: Small balloon expandable valves have higher echocardio-
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graphic transvalvular gradients and rates of prosthesis-patient mismatch (PPM) com-
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pared to larger valves. However, the impact of these echocardiographic findings on
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clinical outcomes is unknown. We sought to determine the clinical outcomes of
20 mm SAPIEN 3 (S3 BEV) compared to larger S3 BEV in relation to echocardiographic hemodynamics.
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Methods: Using the STS/ACC transcatheter valve registry, we performed a
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ables and survival were analyzed. Multivariable logistic regression was used to iden-

propensity-matched comparison of patients undergoing treatment of native aortic
valve stenosis using transfemoral, balloon-expandable implantation of 20 mm and
≥ 23 mm S3 BEVs. Baseline and procedure characteristics, echocardiographic varitify predictors of 1-year mortality.
Results: After propensity matching of the 20 mm and ≥ 23 mm SAPIEN 3 valves,
3,931 pairs with comparable baseline characteristics were identified. Small valves
were associated with significantly higher echocardiographic gradients at discharge
(15.7 ± 7.1 mmHg vs. 11.7 ± 5.5 mmHg, p < 0.0001) and severe PPM rates (21.5%
vs. 9.7%, p < 0.0001). There was no significant difference in 1-year all-cause mortality (20 mm: 13.0% vs. ≥23 mm: 12.7%, p = 0.72) or other major adverse event rates
and outcomes between the two cohorts. Based on a multivariable analysis, elevated
discharge mean gradient (>20 mmHg), severe PPM and the use of 20 mm versus
≥23 mm were not independent predictors of 1-year mortality.
Conclusion: SAPIEN 3 20 mm valves were associated with higher echocardiographic
gradients, and severe PPM rates compared to larger valves but these factors were not
associated with significant differences in 1-year all-cause mortality or rehospitalization.
KEYWORDS

structural heart disease, transcatheter aortic valve replacement, TVT registry
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calculated using the continuity equation. In non-obese (BMI < 30 kg/
m2) patients, PPM was defined as non-significant if EOAi was

Treatment of patients with severe aortic stenosis and small annuli has

>0.85cm2/m2, moderate if >0.65 cm2/m2 and ≤ 0.85 cm2/m2, and

remained a surgical challenge for which transcatheter options have

severe if ≤0.65 cm2/m2. In obese patients (BMI ≥30 kg/m2), non-

1,2

become an acceptable alternative.

These patients can be treated

either with 20 mm balloon expandable valves or 23–26 mm self-

significant

if

EOAi

>0.70cm2/m2,

moderate

if

>0.55 cm2/m2

and ≤ 0.70 cm2/m2, and severe if ≤0.55 cm2/m2.13

expanding valves. Retrospective registries have demonstrated higher

The 20 mm patients were propensity matched with patients

echo gradients in smaller (≤23 mm) balloon expandable valves accom-

receiving ≥23 mm Edwards SAPIEN 3 valves using 25 covariates

panied by higher rates of prosthesis-patient mismatch (PPM)3,4 com-

(Table S1). Missing baseline values were imputed using the Markov-

pared to the self-expanding valve, which have led some operators to

Chain Monte Carlo method prior to modeling. The balance between

utilize echocardiographic valve hemodynamics when choosing trans-

the cohorts was determined by calculating standardized differences

catheter heart valves. However, more recent studies shown no signifi-

for which a difference of less than 0.10 was considered to suggest a

cant differences in transcatheter valve hemodynamics between self-

good balance.

expanding and balloon-expandable valves implanted into small annuli5

Baseline

characteristics

were

compared

between

20 mm

and adverse outcomes associated with PPM are not consistently asso-

and ≥ 23 mm SAPIEN 3 valves. Subsequently, the SAPIEN 3 20 mm

ciated with balloon-expandable valves.6-8 In fact, outcomes from large

patients were compared to a propensity matched cohort of patients

registries have suggested that despite differences in valve hemody-

that received ≥23 mm SAPIEN 3 valves with respect to baseline char-

namics, there may be a survival benefit to the balloon-expandable

acteristics, procedural variables, complications, echocardiographic

9,10

Nonetheless, a prior Society of Thoracic Surgeons (STS)/

parameters, 30-day and 1-year outcomes. Categorical variables were

American College of Cardiology (ACC) Transcatheter Valve Therapy

compared using the Chi-squared test or Fisher's exact test while con-

(TVT) Registry™ report demonstrated a 12.1% rate of severe PPM

tinuous variables utilized the t-test. Statistical significance was deter-

that was associated with a 1.19 adjusted hazard ratio for 1-year mor-

mined using 95% confidence intervals. Time to death survival was

platform.

11

Given the known increase in PPM in patients with small aortic

assessed using the Kaplan–Meier method and statistical significance

annuli in trials,6,12 we sought to describe the real-world experience of

with log-rank test. All P values were 2-sided, and p < 0.05 was consid-

using the 20 mm SAPIEN 3 valves in a large population using data

ered significant for all tests. In addition, multivariable analysis was also

accumulated via the STS/ACC TVT Registry™ (TVT Registry).

performed to identify independent predictors of 1-year mortality in

tality.

patients with TAVR in native valve via transfemoral access. Baseline
characteristics with p value of <0.1 in the univariable analysis were

2

|

METHODS

included in the multivariable model which included 35 covariates
(Table S2). Proportional-hazards assumption was confirmed through

The TVT Registry is a collaborative clinical registry developed by the

testing based on Kolmogorov-type Supremum Test. A Cox regression

STS and the ACC in response to the Centers for Medicare and Medic-

model was used with stepwise selection, which consisted of entering

aid Services national coverage decision (May 2012) requirement for

in the model covariates with p ≤ 0.10 and removing covariates with

national registry participation of all United States transcatheter aortic

p > 0.10. Additional multivariable analyses were performed to assess

valve replacement (TAVR) centers. The TVT Registry uses standard-

the independent impact of discharge hemodynamics (trans-valvular

ized definitions and collates participant-reported data, which includes

echo gradient and the presence of severe PPM), moderate/severe

clinical information such as patient demographics, comorbidities,

paravalvular leak (PVL) and need for new pacemaker implant on

functional status, quality of life indexes, and procedural details and

1-year mortality. All statistical analyses were performed using SAS

outcomes from consecutive patients undergoing TAVR using commer-

version 9.4 (SAS Institute Inc., Cary, North Carolina).

cially approved devices.11 The TVT Registry protocol was granted
a waiver of informed consent by Advarra© and Duke University

3

Institutional Review Boards.

|

RE SU LT S

The SAPIEN 3 20 mm transcatheter heart valve (THV) was commercially approved in June 2015. This analysis is based on patients

From June 2015 until January 2020, 145,917 patients underwent

who underwent transfemoral native TAVR using the SAPIEN 3 or

TAVR with SAPIEN 3 and SAPIEN 3 Ultra and were enrolled in the

SAPIEN 3 Ultra and included in the TVT Registry between June 2015

TVT Registry (Figure 1). Patients who had TAVR with either alterna-

and January 2020. All patients in the study cohort were linked to

tive access or underwent valve-in-valve (ViV) procedure were

CMS claims data, in addition to the follow-up obtained from the TVT

excluded. Among the remaining 132,730 patients, 3,932 underwent

Registry.

native TAVR with SAPIEN 3 20 mm valves and 128,798 with SAPIEN

Standardized definitions of adverse events and outcomes were

3 ≥ 23 mm valves.

based on VARC-2. Procedural, in-hospital, 30-day and 1-year out-

There were several differences in patients receiving 20 mm and

comes were derived from the TVT Registry. PPM was classified based

≥ 23 mm SAPIEN 3 valves (Table S3). Patients receiving 20 mm valves

on

were almost all women (96.4% vs. 46.3%, p value <0.0001). They

discharge

echocardiographic

effective

orifice

area

(EOA),

3
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F I G U R E 1 Flow chart of the
study population. S3, SAPIEN 3; S3U,
SAPIEN 3 Ultra; TAVR, transcatheter
aortic valve replacement; TVT,
transcatheter valve therapy; VITV,
valve in transcatheter valve; ViV,
valve-in-(surgical) valve; Non-TF,
non-transfemoral

were slightly older and have higher surgical risk scores (7.1 ± 4.8%

Meier analysis showed the survival curves comparing 20 mm

vs. 5.8 ± 4.4%, p value <0.0001). Propensity-matching resulted in

and ≥ 23 mm valves were identical out to 1 year (Figure 2(A)). Even

3931 pairs with comparable baseline characteristics (Table 1).

when excluding patients with moderate/severe PVL, no differences in

The procedural variables for the propensity matched 20 mm
and ≥ 23 mm S3 cohorts are similar with some minor differences

survival were seen at 1 year (20 mm 12.3% vs. ≥23 mm 12.1%,
p = 0.248, HR: 1.04 [95% CI: 0.97, 1.11]).

(Table S4). The 20 mm valves were associated with lower rates of

Independent predictors of 1-year mortality were identified using

conscious sedation (47.1% vs. 53.9%, p < 0.0001), and slightly longer

logistic regression. Most of the covariates chosen were statistically

procedure time (98.2 ± 51 vs. 92.6 ± 49 min, p < 0.0001). A lower

significant independent predictors of mortality but only some were

rate of device success (94.7% vs. 97.2%, p < 0.0001) was observed in

truly clinically relevant such as the atrial fibrillation/flutter, patients on

the 20 mm cohort associated with higher rates of moderate–severe

dialysis, severe chronic lung disease, immunocompromised status, and

paravalvular leak (PVL) and elevated post-procedure echo gradients.

moderate–severe tricuspid insufficiency (Table S5). Moderate/severe

There were no differences with respect to device implantation suc-

PVL at discharge was associated with increased mortality at 1 year

cess, conversion to open heart surgery, coronary obstruction or annu-

(Figure S1(A)). Interestingly, moderate/severe PVL and severe PPM

lus rupture.

did not appear to interact, severe PPM was still found to have neutral

As depicted by Table 2, the rate of severe PPM was significantly

effect on mortality when included in the same multivariable analysis

the

as moderate/severe PVL (HR 1.04 [0.94, 1.15], p = 0.44). The need

higher mean gradients observed in the 20 mm cohort (15.7

for new pacemaker was also associated with increased mortality at

vs. 11.7 mmHg, p < 0.0001). The rate of moderate/severe PVL was

1 year (Figure S1(B)). The presence of severe PPM at discharge was

significantly higher in the 20 mm valve cohort at discharge, 30-days

not associated with 1-year all-cause mortality (Figure S1(C)). Concern

and 1-year (Table 2).

for the possibility of the interaction of obesity resulting in over-

higher

(21.5%

vs.

9.7%,

p < 0.0001),

associated

with

The in-hospital and 30-day outcomes of the propensity matched

estimation of PPM prompted the use of BMI adjusted PPM definitions

cohorts had minor differences (Table 3). The most significant differ-

and the rate of severe PPM was recalculated at 16.4% (20 mm) versus

ence noted was in permanent pacemaker implantation (4.3% vs. 8.5%

6.8% (≥23 mm), p < 0.0001. Multivariable analysis showed that the

at 30 days, p < 0.0001). The 30-day stroke rate was slightly higher in

presence of BMI adjusted severe PPM was not associated with

the 20 mm valve patients (2.5% vs. 1.9%, p = 0.05), however the rate

increased 1-year all-cause mortality (HR Severe vs. non-Severe 1.04

of any readmission was lower (7.9% vs. 9.2%, p = 0.04).

[0.94, 1.16], p = 0.436).

At 1-year, there were no differences in death, stroke, any

Interestingly, elevated discharge echo transvalvular mean pres-

readmissions or valve related readmissions between patients receiving

sure gradient was associated with lower all-cause mortality at 1 year

20 mm and ≥ 23 mm SAPIEN 3 valves (Table 4). Symptom burden

(Figure S1(D)). Based on the multivariable analyses moderate/severe

was the same between cohorts as the reported NYHA III/IV and self-

PVL and new pacemaker implant at discharge were independent pre-

reported KCCQ scores were undistinguishable (Table 4). There were

dictors of increased 1-year all-cause mortality (Figure 2(B)). Elevated

slightly higher rates of valve re-intervention of the 20 mm (1.1% vs.

discharge mean gradient (≥ 20 mmHg), severe PPM and the use of

0.6%, p = 0.03) and the 1-year pacemaker rate was significantly lower

20 mm vs. ≥23 mm were not independent predictors of 1-year mor-

(5.2% vs. 9.4%, p < 0.0001) compared to the ≥23 mm cohort. Kaplan–

tality (Figure 2(B)).
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20 mm (n = 3,931)

≥23 mm (n = 3,931)

p value

Age (years)

81.9 ± 8.26

81.9 ± 8.16

0.89

STS risk score (%)

7.0 ± 4.78

7.1 ± 5.49

0.41

Male

142 (3.6)

142 (3.6)

1.0

NYHA III/IV

2,815 (72.2)

2,813 (72.3)

0.94

BMI (kg/m2)

27.2 ± 6.72

27.0 ± 6.20

0.3

PAD

858 (21.8)

852 (21.7)

0.87

Carotid stenosis

984 (25.0)

971 (24.7)

0.73

Atrial fibrillation/flutter

1,083(27.6)

1,119 (28.5)

0.37

Prior stroke

412 (10.5)

409 (10.4)

0.91

Chronic lung disease

1,283 (32.6)

1,338 (34.0)

0.19

Prior PCI

991 (25.2)

970 (24.7)

0.58

Prior CABG

357(9.1)

348 (8.9)

0.72

Porcelain aorta

143 (3.6)

133 (3.4)

0.54

GFR (ml/min/1.73 m2)

58.3 ± 23.86

58.3 ± 23.32

0.97

KCCQ

47.0 ± 24.73

46.4 ± 24.61

0.29

T A B L E 1 Propensity adjusted
baseline characteristics

Note: Data presented as mean ± SD or No. of patients (%).
Abbreviations: BMI, body mass index; CABG, coronary artery bypass graft; GFR, glomerular filtration
rate; KCCQ, Kansas City Cardiomyopathy Questionnaire; No, number; NYHA, New York Heart
Association; PAD, peripheral artery disease; PCI, percutaneous coronary intervention; SD, standard
deviation; STS, Society of Thoracic Surgeons.

4
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DISCUSSION

predictor of mortality, only 40% of patients in the severe PPM subgroup had valve diameters ≤23 mm. With a mean BSA of 1.98 m2

The results of our study are as follows: (1) the vast majority of

(1.8–2.17), it is difficult to reconcile that 26 mm valves could cause

patients receiving SAPIEN 3 20 mm valves are women; (2) compared

severe PPM. Both our 20 mm SAPIEN study and the prior TVT

to implantation of ≥23 mm SAPIEN 3 valves, implantation of a 20 mm

Registry report assessed for PPM at discharge echocardiography.

SAPIEN 3 valve was associated with greater rates of moderate–severe

One difference is that the prior TVT Registry publication includes

PVL, lower incidence of new pacemakers, higher echocardiographic

valve-in-valve procedures and alternative access in contrast to our

gradients, and greater incidence of severe PPM; (3) on multivariable

100% native valve, transfemoral TAVR cohort.

analysis, severe PPM, an echocardiographic gradient >20 mmHg, or

PPM has been shown to have overall neutral impact on mortality

the use of a 20 mm SAPIEN 3 valve were not predictors of increased

in PARTNER pivotal studies. Severe PPM was found in 20% and 14%

1-year mortality. Furthermore, hospital readmissions, symptoms and

of the randomized and non-randomized TAVR cohorts respectively.6

quality of life at 1 year were similar in both cohorts.

There was no overall correlation with severe PPM and survival in the

Relevance of PPM is predominantly described in the surgical

randomized cohort, in fact there appeared to have a slight survival

literature. Meta-analysis of surgical studies found consistently higher

advantage associated with severe PPM at 2 years. Similarly, PPM had

14

hazard ratios for all-cause mortality for any PPM and severe PPM.

no significant association with death in the PARTNER II study.7 An

Examination of the Corevalve US Pivotal High Risk study comparing

analysis to re-stratify patients with PPM according to either echocar-

SAVR to TAVR showed severe PPM to independently predict mortal-

diographic or CT defined parameters to improve prognostication was

ity.15 Investigators observed that patients with smaller annuli more

performed in PARTNER II. TTE and CT defined PPM was discrepant,

frequently manifested severe PPM in the surgical cohort than the

the rate of moderate and severe PPM in the TAVR population was

Corevalve/Evolut THV cohort. Moreover, in patients with small annu-

36% and 9% when characterized by TTE, while CT classified 18% and

lus, the rate of all-cause mortality was twice as high for patients with

6% of the same patients respectively. This suggests discordance

severe PPM, suggesting that PPM played a role in mortality. A follow-

between hemodynamic and anatomic assessment of PPM and may

up Corevalve study, SURTAVI study showed no differences in TAVR

highlight a liability in hemodynamic assessments of valve area given

or SAVR patient survival treated for small annuli despite the higher

the absence of increased mortality with the diagnosis of severe PPM.

rates of severe PPM in the surgical population.12

The most recent pivotal study comparing the SAPIEN 3 valve to

The evidence for PPM in TAVR stems from the TVT Registry

SAVR also demonstrated overall neutral impact of severe PPM on

report describing a 12.1% rate of severe PPM that was associated

mortality.8 The rate of severe PPM was 4.6% and 6.3% in the TAVR

11

with a 1.19 adjusted hazard ratio for 1-year mortality.

Although the

multi-variate analysis identified valves ≤23 mm in diameter as a

and SAVR cohort, respectively. As a collective, PPM was not associated

with

the

composite

endpoint

of

death,

stroke

or

5
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T A B L E 2 Propensity adjusted
echocardiographic outcomes

20 mm (n = 3,931)

≥23 mm (n = 3,931)

p value

Severe PPM

626 (21.5)

288 (9.7)

<0.0001

Mean gradient (mmHg)

15.7 ± 7.09

11.7 ± 5.54

<0.0001

Mean gradient ≥20 mmHg

822 (23.4)

258 (7.4)

<0.0001

None

2,205 (71.1)

2,625 (82.1)

<0.0001

Mild

815 (26.3)

539 (16.9)

<0.0001

Moderate

77 (2.5)

33 (1.0)

<0.0001

Severe

4 (0.1)

1 (0.03)

0.21

Moderate/severe

81 (2.6)

34 (1.1)

<0.0001

Mean gradient

16.8 ± 6.51

12.1 ± 5.34

<0.0001

LVEF (%)

63.1 ± 8.35

61.3 ± 8.81

<0.0001

None

1,468 (57.8)

2018 (76.3)

<0.0001

Mild

936 (36.9)

587 (22.2)

<0.0001

Moderate

127 (5.0)

40 (1.5)

<0.0001

Severe

7 (0.3)

1 (0.04)

0.04

Moderate/severe

134 (5.3)

41 (1.5)

<0.0001

Discharge

Paravalvular leak

30-day

Paravalvular leak

1-year
Mean gradient

18.9 ± 7.70

13.0 ± 6.42

<0.0001

LVEF (%)

63.2 ± 8.19

61.4 ± 8.55

<0.0001

None

756 (58.7)

923 (77.9)

<0.0001

Mild

442 (34.3)

232 (19.6)

<0.0001

Moderate

85 (6.6)

30 (2.5)

<0.0001

Severe

5 (0.4)

0 (0.0)

0.06

Moderate/severe

90 (7.0)

30 (2.5)

<0.0001

Paravalvular leak

Note: Data presented as mean ± SD or No. of patients (%).
Abbreviations: LVEF, left ventricular ejection fraction; No, number; PPM, prosthesis-patient mismatch;
SD, standard deviation.

rehospitalization. However, when analyzing the impact of severe PPM

2-year mortality associated with the self-expanding valve as well as a

on women only, a 3.67-fold increase in mortality at 1-year was

higher risk of ≥ moderate PVL. This discordance in hemodynamics and

observed8 potentially due to smaller surgical valve sizes in women. In

outcomes raises important issues about the flow characteristics of the

contradistinction, our analysis of the TVT Registry SAPIEN 3 20 mm

SAPIEN 3 valve, which might result in an overestimation of transaortic

data was comprised almost entirely of women and those with severe

gradient compared to invasive gradients16 or an underestimation in

PPM had similar outcomes to the entire cohort.

true valve area by echocardiography.17

Continued controversy exists over the why differences in mean

A glaring concern is the relatively high rate of PVL seen in 20 mm

gradients and valve areas favoring one valve type would result in

valve patients. The significantly higher 5.3% rate of 30-day

long-term outcomes that favor the valve with reportedly higher gradi-

moderate–severe PVL is concerning, especially when compared to the

used the French adminis-

1.5% rate of the ≥23 mm cohort. Furthermore, moderate–severe PVL

trative hospital-discharge database to propensity match >10,000 pairs

was associated with a two-fold increase in all-cause mortality at

of patients and showed that the newest iteration of balloon-

1-year (Figure S1(A)). Further analysis of the rates of moderate/severe

expandable transcatheter valve was associated with a lower yearly

PVL at 30-day post-TAVR, demonstrated that the difference in the

incidence

10

ents and smaller valve areas. Deharo et al.

and

rates in patients implanted with small versus large valves decreased

rehospitalization for heart failure compared to the self-expanding

yearly (from 7.1% in 2015 to 1.4% in 2019) (Figure S2(A)). We hypoth-

valve. Similar results were found by van Belle et al.9 with increased

esize this decrease in PVL rates is related to an increase in CT based

of

all-cause

death,

cardiovascular

death,

6
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20 mm (n = 3,931)

≥23 mm (n = 3,931)

All-cause mortality

64 (1.6)

76 (1.9)

0.31

Cardiac death

p value

T A B L E 3 Propensity Adjusted InHospital and 30-Day Outcomes

In-hospital outcomes

34 (0.9)

38 (1.0)

0.64

Stroke

74 (1.9)

60 (1.5)

0.22

Aortic valve re-intervention

28 (0.7)

18 (0.5)

0.14

Major vascular complication

72 (1.8)

56 (1.4)

0.15

New requirement for dialysis

20 (0.5)

20 (0.5)

1

New onset of atrial fibrillation

68 (1.7)

74 (1.9)

0.61

New pacemaker

149 (3.8)

277 (7.0)

<0.0001

30-day outcomes
All-cause mortality

105 (2.8)

99 (2.6)

0.69

Cardiac death

38 (1.0)

42 (1.1)

0.64

O:E

0.38

0.35

Stroke

98 (2.5)

72 (1.9)

0.05

Aortic valve re-intervention

28 (0.7)

19 (0.5)

0.19

Life-threatening bleeding

7 (0.2)

8 (0.2)

0.79

Major vascular complication

79 (2.0)

62 (1.6)

0.15

New requirement for dialysis

21 (0.6)

21 (0.6)

0.99

New pacemaker

165 (4.3)

324 (8.5)

<0.0001

Any readmission

292 (7.9)

339 (9.2)

0.04

Valve related readmission

25 (0.7)

21 (0.6)

0.57

NYHA III/IV

277 (9.2)

242 (7.9)

0.07

KCCQ

75.1 ± 21.60

74.5 ± 22.31

0.32

Note: Data presented as mean ± SD or No. of patients (%).
Abbreviations: NYHA, New York Heart Association; KCCQ, Kansas City Cardiomyopathy Questionnaire;
No, number; PPM, prosthesis-patient mismatch; SD, standard deviation.

All-cause mortality
Cardiac death

20 mm (n = 3,931)

≥23 mm (n = 3,931)

405 (13.0)

362 (12.7)

0.72

p value

76 (2.3)

69 (2.2)

0.78

Stroke

146 (4.3)

117 (3.7)

0.14

Aortic valve re-intervention

39 (1.1)

21 (0.6)

0.03

Life-threatening bleeding

12 (0.4)

13 (0.4)

0.76

Major vascular complication

84 (2.2)

68 (1.8)

0.21

New requirement for dialysis

27 (0.8)

26 (0.8)

0.96

New pacemaker

190 (5.2)

349 (9.4)

<0.0001

Any readmission

806 (26.4)

784 (26.9)

0.31

Valve related readmission

62 (2.0)

49 (1.7)

0.38

NYHA III/IV

138 (8.3)

100 (6.9)

0.12

KCCQ

78.6 ± 20.84

77.9 ± 21.13

0.33

TABLE 4
outcomes

Propensity adjusted 1 year

Note: Data presented as mean ± SD or No. of patients (%).
Abbreviations: NYHA, New York Heart Association; KCCQ, Kansas City Cardiomyopathy Questionnaire;
No, number; PPM, prosthesis-patient mismatch; SD, standard deviation.

valve sizing (Figure S2(B)). Improvement in valve sizing, implantation

One interesting observation was the improved survival in patients

technique and possibly alternative valve selection may explain

with higher gradients. A potential explanation for this phenomenon is

improved PVL rates (Figure S2(B)).

that patients with lower gradients include a group with low-flow,
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F I G U R E 2 Kaplan–Meier
estimate of 1-year all-cause mortality
by valve size (A) and adjusted
independent predictors of mortality at
1 year (B) [Color figure can be viewed
at wileyonlinelibrary.com]

low-gradient aortic valve stenosis with lower stroke volume, which is

propensity matching, it reduced the sample size and limited the ability

known to be associated with decreased survival. From a retrospective

to identify mortality predictors, Unfortunately, patient level CT data

analysis of a Corevalve study, low-gradient normal LVEF patients

are not available to corroborate our claims about CT sizing and all of

were found to have a 1 year all-cause mortality of 21% with only a

the echocardiographic data is self-reported. In the TVT Registry data-

18

The TOPAS-TAVI study

base, EOA required to estimate PPM is available at discharge only and

enrolled patients with low-flow, low-gradient aortic valve stenosis

not at 30-day echocardiography, therefore PPM may have been

with reduced ejection fraction and similarly had high rates of all-cause

assessed while the patient was potentially in a low-flow state from

death but less cardiac mortality (all cause death 32.3%, cardiac death

recent valve implantation. Additionally, the data are short-term and

11.5% rate of cardiovascular mortality.

19

17.6%).

Both the Corevalve extended registry and TOPAS-TAVI

reported stroke volume indexes of 34.6 ± 8.9 ml/m2 and 32.9

the impact of higher gradients or PPM may require more time to
develop.

± 10.1 ml/m2 respectively. It is possible that the low gradients postprocedure in our TVT Registry analysis include a group of patients
with lower stroke volume with a higher risk of non-cardiac death.20

5

|

CONC LU SION

With prospective studies using comprehensive echocardiographic
assessment including stroke volume, investigators may someday bet-

This analysis demonstrates the safety and effectiveness of the

ter understand the prognostic relevance of elevated mean gradient

Edwards SAPIEN 20 mm THV relative to its larger counterparts.

following TAVR.

Despite slightly higher gradients and higher rates of PPM, patients
have identical symptom relief and survival at 12 months. While PVL
rates were higher with SAPIEN 3 20 mm valves, we attribute this to a

4.1

|

Limitations

valve sizing learning curve and with improvement with CT utilization,
the SAPIEN 3 PVL appeared to improve. The findings suggest that

This is a retrospective analysis of a clinical registry and outcomes are

echocardiographic PPM may not influence outcomes and more

corroborated by Medicare claims data. As such, the conclusions drawn

research is needed to better understand the discrepancies in valve

are hypothesis gathering only. Nevertheless, the robustness of the

prosthesis size and echocardiographically measured EOA. Further-

propensity-matching does give more weight to the comparisons

more, longer follow up will be needed to better understand the impact

drawn

between

20 mm

and

≥ 23 mm

valves.

Although

comparisons between the two cohorts were stronger with use of

of higher gradients and PPM on TAVR patients as the effect of such
variables may not be detected this early in their clinical course.
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